跳至主要内容
临床试验/DRKS00003958
DRKS00003958已完成未知

A Multicenter Randomized, Controlled Clinical Study on the Effect of a Probiotic (Lactobacillus casei Shirota) on the Immune Response to Influenza Vaccination

Yakult Honsha Co., Ltd.0 个研究点目标入组 638 人开始时间: 2012年6月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
638

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 one(—)
性别
All

入选标准

  • ? Free-living adults aged = 50 years willing to have influenza vaccination season 2011/2012
  • ? willingness to abstain from food and supplements containing probiotics, prebiotics and other fermented products
  • ? written informed consent

排除标准

  • ? Subjects enrolled in another clinical study in the last 4 weeks
  • ? Subjects already vaccinated against influenza during 2011-2012 with either the influenza vaccine used in the present study or another influenza vaccine.
  • ? Subjects previously vaccinated against influenza during 2010-2011
  • ? Subjects previously vaccinated against pandemic influenza in 2009 or 2010 with an influenza pandemic vaccine (A/H1N1)
  • ? known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression)
  • ? active autoimmune diseases
  • ? allergy or hypersensitivity to any component of the vaccine (e. g. chicken egg protein, certain antibiotics)
  • ? allergy or hypersensitivity to any component of the test product (e.g. milk protein)
  • ? suffering from influenza or influenza-like illness in the current winter season (since Nov. 2011)
  • ? symptoms of common infectious diseases (CID) of the airways or other organ systems e.g. gastrointestinal tract in the last 4 weeks before inclusion.
  • ? severe chronic disease (cancer, IBD, malabsorption, malnutrition, chronic inflammatory diseases, renal, hepatic or cardiac diseases, respiratory insufficiency)
  • ? chronic abdominal pain
  • ? systemic treatment or topical treatment likely to interfere with evaluation of the study parameters: antibiotics, intestinal or respiratory antiseptics, antirheumatics, antiphlogistics (except aspirin or equivalent products preventing from aggregation of platelets or blood clotting) and steroids prescribed in chronic inflammatory diseases
  • ? other treatments likely to interfere with study outcome (e.g. laxatives, body weight management and/or medication)
  • ? lactose intolerance
  • ? diabetes mellitus on drug therapy
  • ? severe neurological, cognitive or psychiatric diseases
  • ? surgery or intervention requiring general anaesthesia within 2 months before the study
  • ? pregnancy or lactation
  • ? eating disorders or special diets (e.g. vegan)
  • ? alcohol and products abuse
  • ? legal incapacity

研究者

相似试验